New Gilead CEO O'Day Says Boosting Drug Pipeline Is Top Priority

(Bloomberg) -- Gilead Sciences Inc. Chief Executive Officer Daniel O’Day, who took the reins in March, said one of his top priorities is bolstering the biotechnology giant’s drug pipeline.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.